Gilead Sciences, Inc. (BIT:1GILD)

Market Cap	127.57B
Revenue (ttm)	24.58B
Net Income (ttm)	5.37B
Shares Out	n/a
EPS (ttm)	4.27
PE Ratio	23.74
Forward PE	14.10
Dividend	2.16 (2.10%)
Ex-Dividend Date	Mar 13, 2025

Volume	401
Average Volume	203
Open	102.80
Previous Close	102.68
Day's Range	102.04 - 102.90
52-Week Range	65.17 - 111.00
Beta	0.35
RSI	61.80
Earnings Date	Aug 1, 2025

About Veren

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in CAD